Citations

Clear

118 citation(s) found for "Bower, James".

Prevalence of sleep disorders in Parkinson’s disease patients in Ethiopia
Melka, Dereje , Tafesse, Abenet , Bower, James H., Assefa, Demeke

Mayo Clinic

No container title available | March 20, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.442/v2 Get It

Abstract Background: Non motor symptoms (NMS) of Parkinson’s disease (PD) are common and can be more disabling than motor symptoms.Sleep disorders can be seen in up to 98% of patients with Parkinson disease. Poor sleep quality has been associated with poverty and race, and yet there has been no prior report on sleep disorders in those with PD living in sub Saharan Africa. We wished to document the prevalence of sleep disorders in PD patients in Ethiopia. Methods: We conducted a cross-sectional point prevalence study from July 1 to October 30, 2015 of all patients attending the neurology outpatient department in Tikur Anbessa and Zewuditu Memorial Hospitals, Addis Ababa, Ethiopia. Demographic data, clinical history and physical examination findings were collected from participants using a structured questionnaire. We used the Parkinson’s disease sleep scale version two (PDSS-2) and Epworth Sleepiness Scale (ESS) to assess the sleep symptoms. Results: Of the 155 patients surveyed, all patients reported some sleep problem. Over 43.9% of patients had a PDSS score > 18. Presence of previous history of sleep disturbance before PD motor symptoms (OR 3.54; 95% CI 1.61-7.76, p=0.001) and unemployment (OR 2.27; 95% CI 1.07-4.79, p=0.023) associated with a high PDSS-2 score. The median score of ESS was 9 (IQR = 5-12), with 77/155 (49.7%) of the patients having possible or definite excessive daytime somnolence. Conclusions: In Ethiopian PD patients, the prevalence of those with severe sleep disorders is the highest reported to date. The prevalence of possible/definite EDS is amongst the highest in the world. Further investigation into whether poverty or race explains this finding is needed.
Prevalence of sleep disorders in Parkinson’s disease patients in Ethiopia
Melka, Dereje , Tafesse, Abenet , Bower, James H., Assefa, Demeke

Mayo Clinic

No container title available | March 13, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.442/v1 Get It

Abstract ABSTRACT Background: Non motor symptoms (NMS) of Parkinson’s disease (PD) are common and can be more disabling than motor symptoms. Sleep disorders can be seen in up to 98% of patients with Parkinson disease. Poor sleep quality has been associated with poverty and race, and yet there has been no prior report on sleep disorders in those with PD living in sub Saharan Africa. We wished to document the prevalence of sleep disorders in PD patients in Ethiopia. Methods: We conducted a cross-sectional point prevalence study from July 1 to October 30, 2015 of all patients attending the neurology outpatient department in Tikur Anbessa and Zewuditu Memorial Hospitals, Addis Ababa, Ethiopia. Demographic data, clinical history and physical examination findings were collected from participants using a structured questionnaire. We used the Parkinson’s disease sleep scale version two (PDSS-2) and Epworth Sleepiness Scale (ESS) to assess the sleep symptoms. Results: Of the 155 patients surveyed, all patients reported some sleep problem. Over 23% of patients had a PDSS score > 30. Hoehn and Yahr score > 3 (OR 6.16; 95% CI 1.59-23.9, p=0.009) and PD symptom duration > 5 yrs (OR 5.11; 95% CI 1.41-18.5, p=.013) associated with a high PDSS-2 score. The median score of ESS was 9 (IQR = 5-12), with 77/155 (49.7%) of the patients having possible or definite excessive daytime somnolence. Conclusions: In Ethiopian PD patients, the prevalence of those with severe sleep disorders is the highest reported to date. The prevalence of possible/definite EDS is amongst the highest in the world. Further investigation into whether poverty or race explains this finding is needed. Keywords: Parkinson’s disease, Sleep disorders, Africa, poverty
Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy
Ali, Farwa , Martin, Peter R. , Botha, Hugo , Ahlskog, J. Eric , Bower, James H., Masumoto, Joseph Y., Maraganore, Demetrius M. , Hassan, Anhar , Eggers, Scott D.Z. , Drubach, Daniel A., Petersen, Ronald C. , Dunkley, Erika Driver, Gerpen, Jay Van, Uitti, Ryan J. , Whitwell, Jennifer L., Josephs, Keith A. , Eggers, Scott, Drubach, Daniel, Van Gerpen, Jay, Uitti, Ryan, Botha, Hugo , Boeve, Bradley F. , Knopman, David S. , Gerpen, Jay A. van, Whitwell, Jennifer , Dickson, Dennis W.

Mayo Clinic

Movement Disorders | February 6, 2019 | Volume: 34 | Issue: 8 | Pages: 1144-1153

10.1002/mds.27619 | PMID 30726566 Get It

Abstract Background In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. Methods Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3‐year cutoff. Results A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. Conclusion The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria. © 2019 International Parkinson and Movement Disorder Society
Levodopa-induced dyskinesia in Parkinson disease
Turcano, Pierpaolo , Mielke, Michelle M. , Bower, James H., Parisi, Joseph E. , Cutsforth‐Gregory, Jeremy K. , Ahlskog, J. Eric , Savica, Rodolfo , Mielke, Michelle M

Mayo Clinic

Neurology | November 7, 2018 | Volume: 91 | Issue: 24 | Pages: No page available

10.1212/wnl.0000000000006643 | PMID 30404780 Get It

Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy
Rocca, Walter A. , Geda, Yonas E. , Gostout, Bobbie S., Bower, James H., Maraganore, Demetrius M. , Melton, L. Joseph , Geda, Yonas E , Grossardt, Brandon R. , Andrade, Mariza de

Mayo Clinic

Menopause | October 25, 2018 | Volume: 25 | Issue: 11 | Pages: 1275-1285

10.1097/gme.0000000000001229 | PMID 30358723 Get It

Abstract Objective: We studied the long-term risk of depressive and anxiety symptoms in women who underwent bilateral oophorectomy before menopause. Design: We conducted a cohort study among all women residing in Olmsted County, MN, who underwent bilateral oophorectomy before the onset of menopause for a noncancer indication from 1950 through 1987. Each member of the bilateral oophorectomy cohort was matched by age with a referent woman from the same population who had not undergone an oophorectomy. In total, we studied 666 women with bilateral oophorectomy and 673 referent women. Women were followed for a median of 24 years, and depressive and anxiety symptoms were assessed using a structured questionnaire via a direct or proxy telephone interview performed from 2001 through 2006. Results: Women who underwent bilateral oophorectomy before the onset of menopause had an increased risk of depressive symptoms diagnosed by a physician (hazard ratio = 1.54, 95% CI: 1.04-2.26, adjusted for age, education, and type of interview) and of anxiety symptoms (adjusted hazard ratio = 2.29, 95% CI: 1.33-3.95) compared with referent women. The findings remained consistent after excluding depressive or anxiety symptoms that first occurred within 10 years after oophorectomy. The associations were greater with younger age at oophorectomy but did not vary across indications for the oophorectomy. In addition, treatment with estrogen to age 50 years in women who underwent bilateral oophorectomy at younger ages did not modify the risk. Conclusions: Bilateral oophorectomy performed before the onset of menopause is associated with an increased long-term risk of depressive and anxiety symptoms.
Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders
Hinson, Shannon R., López‐Chiriboga, A. Sebastian , Bower, James H., Matsumoto, Joseph Y., Hassan, Anhar , Basal, Eati, Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | January 25, 2018 | Volume: 5 | Issue: 2 | Pages: No page available

10.1212/nxi.0000000000000438 | PMID 29464188 Get It

Parkinson disease with and without Dementia: A prevalence study and future projections
Savica, Rodolfo , Rocca, Walter A. , Bower, James H., Grossardt, Brandon R. , Rocca, Walter A

Mayo Clinic

Movement Disorders | January 22, 2018 | Volume: 33 | Issue: 4 | Pages: 537-543

10.1002/mds.27277 | PMID 29356127 Get It

ABSTRACTBackground: Limited population‐based information is available on the co‐occurrence of dementia and PD. However, projecting the prevalence of PD with and without dementia during the next 50 years is crucial for planning public‐health and patient‐care initiatives.Objectives: The objective of this study was to project the prevalence of PD with and without dementia in the United States by 2060.Methods: We used the Rochester Epidemiology Project medical records‐linkage system to identify all persons with PD with or without dementia residing in Olmsted County, Minnesota, on January 1, 2006. A movement disorders specialist reviewed the complete medical records of each person to confirm the presence of PD. We calculated the age‐ and sex‐specific prevalence of PD with and without dementia and projected U.S. prevalence through 2060.Results: We identified 296 persons with PD with and without dementia on the prevalence date (187 men, 109 women); the overall prevalence increased with age from 0.01% (30‐39 years) to 2.83% (≥90 years). The prevalence of PD without dementia increased with age from 0.01% (30‐39 years) to 1.25% (≥90 years). The prevalence of PD with dementia increased with age from 0.10% (60‐69 years) to 1.59% (≥90 years). The prevalence was higher in men than in women for all subtypes and all age groups. We project by 2060 an approximate doubling of the number of persons with PD without dementia and a tripling of the number of persons with PD with dementia in the United States.Conclusions: The prevalence of PD with and without dementia increases with age and is higher in men than women. We project that the number of persons with PD in the United States will increase substantially by 2060. © 2018 International Parkinson and Movement Disorder Society
Prevalence of and indications for antipsychotic use in Parkinson's disease
Bower, James H., Rocca, Walter A. , Savica, Rodolfo , Grossardt, Brandon R. , Rocca, Walter A

Mayo Clinic

Movement Disorders | December 26, 2017 | Volume: 33 | Issue: 2 | Pages: 325-328

10.1002/mds.27256 | PMID 29278275 Get It

ABSTRACTBackground: The prevalence of patients with PD taking antipsychotics is unknown.Objective: To measure the prevalence of patients with PD taking antipsychotics.Methods: We used the medical records‐linkage system of the Rochester Epidemiology Project to study the use of antipsychotic medication in all persons with Parkinson disease in Olmsted County, Minnesota on 1 January 2006.Results: There were 296 patients with PD in Olmsted County on 1 January 2006. The overall prevalence of antipsychotic use was 9.8% (29 of 296); 95.5% (28 of 29) of the patients had dementia when initiating antipsychotics. The most frequent indication (71.4%; 20 of 28) was psychosis or behavior threatening to the patient or others.Conclusions: The prevalence of antipsychotic use in patients with PD is lower than expected from previously reported cumulative incidences. Dementia is highly prevalent in those starting antipsychotics. Most of the patients on antipsychotics had a reasonable risk‐benefit ratio for taking them. © 2017 International Parkinson and Movement Disorder Society
Clinicopathologic discrepancies in a population‐based incidence study of parkinsonism in olmsted county: 1991‐2010
Turcano, Pierpaolo , Mielke, Michelle M. , Josephs, Keith A. , Bower, James H., Parisi, Joseph E. , Savica, Rodolfo , Mielke, Michelle M , Boeve, Bradley F.

Mayo Clinic

Movement Disorders | August 26, 2017 | Volume: 32 | Issue: 10 | Pages: 1439-1446

10.1002/mds.27125 | PMID 28843020 Get It

ABSTRACTObjective: The purpose of this study was to examine the discrepancies between the clinical diagnosis of parkinsonism and neuropathological findings in a population‐based cohort with parkinsonian disorders.Background: The specific clinical diagnosis of parkinsonism is challenging, and definite confirmation requires neuropathological evaluation. Currently, autopsies are seldom performed, and most brain autopsies represent atypical or diagnostically unresolved cases.Methods: We used a defined population‐based incidence cohort with clinical parkinsonism (n = 669) from the Rochester Epidemiology Project in Olmsted County, Minnesota, 1991‐2010. We reviewed reports of all patients who underwent neuropathologic examination at autopsy (n = 60; 9%) and applied consensus pathologic guidelines for neurodegenerative disease diagnosis.Results: Among the 60 patients examined pathologically, the median time from the last recorded clinical diagnosis to death was 7 years (range from 2 to 17 years). Clinical–pathological concordance was found in 52 cases (86.7%), whereas 8 (13.3%) had a clinical‐pathological discrepancy. Four patients with a clinical diagnosis of idiopathic Parkinson's disease had no pathological evidence of Lewy bodies or α‐synucleinopathy; of these, pathological diagnoses were Alzheimer's disease (2 cases), progressive supranuclear palsy (1 case), and vascular parkinsonism (1 case). Two patients with clinical diagnoses of "dementia with Lewy bodies" and one patient with an "unspecified parkinsonism" had a pathological diagnosis of Alzheimer's disease without concomitant α‐synuclein lesions. One patient with clinically diagnosed "progressive supranuclear palsy" had indeterminate pathological findings without α‐synuclein or Aβ‐ or tau‐immunoreactive lesions at autopsy.Conclusions: Overall, the clinical diagnoses of parkinsonian subtypes had good concordance with pathological confirmation (86.7%). However, clinical–pathological discrepancies were documented in 13.3%. © 2017 International Parkinson and Movement Disorder Society
Fragile X‐associated Tremor/Ataxia Syndrome in an Adolescent Female
Mittal, Shivam Om , Mack, Kenneth J. , Bower, James H., Mack, Kenneth, Mittal, Shivam Om

Mayo Clinic

Movement Disorders Clinical Practice | May 28, 2017 | Volume: 4 | Issue: 5 | Pages: 778-780

10.1002/mdc3.12513 | PMID 30838288 Get It

View Supplementary Video 1